Skip to main content

Table 3 Unadjusted direct mean annual asthma-related mean costs by category of service and severity

From: Health care costs and resource utilization for different asthma severity stages in Colombia: a claims data analysis

Service a Total
n = 20,410
Mild intermittent n = 14,191 Mild Persistent n = 3680 Moderate Persistent n = 1408 Severe persistent n = 1131 p-value b
Medical services c
 ED visits $6 (39.3) $21 (57) $26 (78) $20 (87) 0.187
 Hospitalizations $105 (946) $239 (1492) $368 (1838) $662 (2027) 0.000
 Specialized physician visits $20 (47) $15 (35) $23 (52) $38 (66) $58 (91) 0.000
 General physician visits $37 (61) $30 (39) $41 (59) $54 (77) $100 (158) 0.000
 Other ambulatory services $7 (68) $5 (61) $9 (85) $10 (49) $22 (99) 0.000
 Any medical service d $178 (958) $51 (76) $335 (1489) $498 (1840) $865 (2050) 0.000
Asthma medication prescriptions c
 Controller medications
  ICS $20 (124) $5 (52) $28 (117) $84 (269) $101 (306) 0.000
  ICS + LABA $24 (211) $0.7 (19) $12 (115) $147 (513) $208 (606) 0.000
  LABA $0.5 (16) $0 (2) $0.7 (14) $0.8 (11) $5 (62) 0.000
  LM $12 (89) $0 (0) $10 (61) $37 (143) $137 (296) 0.000
 Rescue Medications
  Oral corticosteroids $14 (74) $0.3 (7) $15 (36) $48 (100) $138 (249) 0.000
  SABA $25 (127) $3 (27) $38 (114) $98 (231) $166 (375) 0.000
  Any medication e $152 (780) $16 (108) $147 (320) $563 (895) $1370 (2755) 0.000
Total mean costs f $331 (1278) $67 (134) $482 (1506) $1061 (1983) $2235 (3426) 0.000
  1. a Mean values and their (SD) are reported and were calculated using the total number of subjects in each column as denominator
  2. b Welch analysis of variance-ANOVA test
  3. c One patient may contribute to the costs of different medical services or prescriptions
  4. d, e, f Mean values represent the sum of costs derived from all medical services d, medications e (or both f ) presented during the cost-analysis period and divided by the total number of subjects in each disease category.
  5. ED emergency department; ICS inhaled corticosteroids; ICS+LABA inhaled corticosteroids-long acting B2 agonist combination; LABA long acting B2 agonist; LM leukotriene modifiers; SABA short acting B2 agonist